Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Mar 1;109(5):1810-6.
doi: 10.1182/blood-2006-08-041152. Epub 2006 Nov 9.

End points to establish the efficacy of new agents in the treatment of acute leukemia

Frederick R Appelbaum  1 , Daniel Rosenblum, Robert J Arceci, William L Carroll, Philip P Breitfeld, Stephen J Forman, Richard A Larson, Stephanie J Lee, Sharon B Murphy, Susan O'Brien, Jerald Radich, Nancy S Scher, Franklin O Smith, Richard M Stone, Martin S Tallman
Affiliations
Free article

End points to establish the efficacy of new agents in the treatment of acute leukemia

Frederick R Appelbaum et al. Blood. .
Free article

Abstract

Federal regulations provide 2 pathways for approval of new agents for the treatment of acute leukemia, regular and accelerated approval. Regular approval requires evidence of clinical benefit, which is generally defined as either prolongation of life or improved quality of life, or an effect on an end point established as a surrogate for clinical benefit. Accelerated approval can be obtained based on demonstration of an effect on a surrogate measure "reasonably likely" to predict clinical benefit, but requires demonstration of clinical benefit after approval as well. The acute leukemias are a heterogeneous and relatively uncommon group of diseases. The design and execution of prospective randomized clinical trials demonstrating prolongation of life or improved quality of life for patients with these disorders can be difficult and costly and require lengthy follow-up. Thus, the development of novel trial design and inclusion of validated surrogate markers for clinical benefit are needed. To explore some of the issues pertinent to the choice of end points for drug approval in acute leukemia, the Food and Drug Administration invited the American Society of Hematology to participate in the organization and conduct of a joint workshop. In this report, we present the results of that effort.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Substances